Bioline RX Ltd Sponsored ADR (BLRX) Q2 2026 Earnings Report

The call was broadly positive, driven by strong GLIX1 clinical enrollment and early safety and tolerability, encouraging glioblastoma and ovarian-cancer preclinical results, continued PDAC trial enrollment, APHEXDA royalty generation, and a cash runway extending into the first half of 2027. Offsetting points included a higher quarterly net loss, flat revenue, uncertainty around the evolving PDAC treatment landscape, and the substantial work still required to expand APHEXDA adoption.

BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.